Table 4.

Antiviral activities of ML-OVA against infection by HIV-1, HIV-2, SHIV, SIV and HSV-2 strains.

Virus strain	Inhibitory activity (Mean ± SD, μM)a
	IC50	IC90
Laboratory-adapted HIV-1 strains
IIIB (X4)	0.023 ± 0.004	0.057 ± 0.004
MN (X4)	0.151 ± 0.008	0.821 ± 0.103
RF (X4R5)	0.034 ± 0.005	0.147 ± 0.059
BaL (R5)	0.690 ± 0.109	2.236 ± 1.184
Primary HIV-1 strains
UG94103(clade A, X4R5)	0.561 ± 0.159	2.520 ± 1.231
92US657 (clade B, R5)	2.107 ± 0.263	9.357 ± 1.939
93IN101 (clade C, R5)	1.208 ± 0.535	4.946 ± 0.632
BCF02 (clade O, R5)	0.067 ± 0.004	0.188 ± .0.010
Ru570 (clade G, R5)	4.299 ± 0.298	9.332 ± 0.594
Drug-resistant HIV-1
AZT-R b	0.296 ± 0.052	1.099 ± 0.773
NL4-3D36Gc	0.104 ± 0.019	0.591 ± 0.059
NL4-3(36G)V38A c	0.185 ± 0.027	0.543 ± 0.026
NL4-3(36G)V38E/N42T c	0.156 ± 0.082	0.992 ± 0.438
HIV-2
ROD	6.079 ± 1.907	12.59 ± 3.022
SIV
mac 251 32H	0.307 ± 0.174	6.128 ± 2.078
SHIV
SF33A (X4)	0.189 ± 0.103	1.505 ± 0.872
SF162P3 (R5)	1.312 ± 0.688	11.63 ± 5.477
HSV
HSV-2 strain 333	39.06 ± 2.316	69.49 ± 3.145

^aThe measurements were performed in triplicate, and the experiment was repeated at least twice;

^bRTI-resistant strain;

^c Enfuvirtide-resistant variants.